|
End-of-day quote
Wiener Boerse
2026-09-08
|
5-day change | 1st Jan Change | ||
| 208.10 EUR | -1.89% |
|
-6.13% | -12.34% |
| 09-10 | UCB: A rare window of affordability |  |
| 09-09 | UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
UCB(UCB)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
UCB(UCB)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
- Stock Market
- Stocks
- UCB Stock
- UCB Stock
- Consensus UCB SA
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
